Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4Gastrointestinal 4

Conditions

Gastrointestinal Stromal Tumors 4

Interventions

Sunitinib 16Imatinib Mesylate 13nilotinib 8ripretinib 4regorafenib 4avapritinib 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3pexidartinib 2pembrolizumab 2Bevacizumab 2trametinib 1tinostamustine 1spartalizumab 1romidepsin 1ponatinib 1pazopanib 1palbociclib 1olaratumab 1guadecitabine 1ferric carboxymaltose 1epacadostat 1dabrafenib 1cediranib 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sorafenib 1STA 9090 1Observation 1Iron-Dextran Complex 1Indocyanine Green 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Stromal Tumors × ripretinib × Clear all
NCT04633122 2026-04-03

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Zai Lab (Hong Kong), Ltd.

Phase 2 Completed
108 enrolled 11 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03673501 2026-02-05

INTRIGUE

Deciphera Pharmaceuticals, LLC

Phase 3 Active not recruiting
453 enrolled 20 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04282980 2025-03-03

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

Zai Lab (Hong Kong), Ltd.

Phase 2 Completed
39 enrolled 13 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03353753 2022-11-21

INVICTUS

Deciphera Pharmaceuticals, LLC

Phase 3 Completed
129 enrolled 19 charts 1 FDA
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡